PI3K Activation and NIS Expression in Breast Cancer
Author Information
Author(s): Katherine A. B. Knostman, James A. McCubrey, Carl D. Morrison, Zhaoxia Zhang, Charles C. Capen, Sissy M. Jhiang
Primary Institution: The Ohio State University
Hypothesis
Does PI3K signaling affect NIS expression and iodide uptake in breast cancer?
Conclusion
The PI3K pathway likely plays a major role in the discordance between NIS expression and iodide uptake in breast cancer patients.
Supporting Evidence
- PI3K activation leads to underglycosylated NIS protein levels.
- NIS expression was found in 80% of human breast tumors.
- Only 20% of tumors were NIS-negative.
- 58% of tumors had primarily intracellular NIS expression.
- NIS-positive tumors were more likely to have PI3K activation.
- Stable PI3K activation decreased NIS-mediated iodide uptake.
- Transient PI3K activation also impaired NIS function.
- Loss of PTEN was associated with marked intracellular NIS expression.
Takeaway
This study found that a protein called NIS, which helps absorb iodide, doesn't work well in breast cancer because of a signaling pathway called PI3K.
Methodology
NIS expression and function were analyzed in MCF-7 cells using Western blot, immunofluorescence, and radioiodide uptake assays.
Potential Biases
Potential bias in sample selection and the reliance on specific cell lines may affect generalizability.
Limitations
The study primarily focused on one breast cancer cell line and a limited number of human samples.
Participant Demographics
Patients had an average age of 42.26 years, with 89% Caucasian and 11% African-American.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website